Brief: Palatin Technologies reports positive interim analysis in Phase 3 pivotal study of Pl9643 in patients with dry eye disease
16/08/2022 12:38
Aug 16 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN REPORTS POSITIVE INTERIM ANALYSIS IN PHASE 3
PIVOTAL
STUDY OF PL9643 IN PATIENTS WITH DRY EYE DISEASE
* PALATIN TECHNOLOGIES INC - INDEPENDENT DATA MONITORING
COMMITTEE
RECOMMENDS CONTINUING STUDY WITH SAMPLE SIZE TARGET OF UP TO 350
PATIENTS
* PALATIN TECHNOLOGIES INC - NO SAFETY CONCERNS IDENTIFIED
* PALATIN TECHNOLOGIES INC - TOPLINE RESULTS CURRENTLY
EXPECTED Q2
CALENDAR 2023
Source text for Eikon: ID:nPn8kJDBqa
Further company coverage: PTN.A
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity